Location: Fuzhou
Synced from ClinicalTrials.gov · August 07, 2026
Clinical studies recruiting near Fuzhou
Studies with at least one listed site matching this
location on the public registry. Each page explains the study in plain
language, with locations and study-team contacts.
Clinicians: generate a
printable list for your patient →
🔍 Search another city or condition
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav Phase 3 · Fujian Medical University Union Hospital · Pfizer · NCT05020236 Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre Phase 3 · Fujian Provincial Hospital · Tasly Pharmaceutical Group Co., Ltd · NCT07687186 Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2 · Department of Nuclear Medicine, First Affiliated Hospital of · First Affiliated Hospital of Fujian Medical University · NCT07363486 Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor Phase 1/Phase 2 · Fujian provincial cancer hospital · Sichuan Enray Pharmaceutical Sciences Company · NCT07433283 A Registered Cohort Study on Charcot-Marie-Tooth Disease Phase N/A · First Affiliated Hospital of Fujian Medical University · Ning Wang, MD., PhD. · NCT04010188 Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorec Phase 2 · Fujian Cancer Hospital · Fudan University · NCT06521866 Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC Phase 3 · Fujian Medical University Union Hospital · Eye & ENT Hospital of Fudan University · NCT06235203 Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Phase 2/Phase 3 · Local Institution - 0048 · Bristol-Myers Squibb · NCT07106762 This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in Phase 3 · Fujian Cancer Hospital · Pfizer · NCT06758401 Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Mod Phase 3 · Fujian Medical University Union Hospital · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06682169 A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Phase 2 · Mengchao Hepatobiliary Hospital, Fujian Medical University · Meng Chao Hepatobiliary Hospital of Fujian Medical Universit · NCT06280105 A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves T Phase 1 · Mengchao Hepatobiliary Hospital of Fujian Medical University · AbbVie · NCT06487559 PulseSelect™ PFA Global Registry Phase N/A · Fujian Provincial Hospital · Medtronic Cardiac Ablation Solutions · NCT06393920 Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding Phase N/A · First Affiliated Hospital of Fujian Medical University · Xingshun Qi · NCT04662918 Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC Phase 2 · Fujian Medical University Union Hospital · Guangdong Association of Clinical Trials · NCT05536505 A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer Phase 1/Phase 2 · Fujian Provincial Cancer Hospital · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06431490 Artificial Intelligence-driven Virtual Standardized Pediatric Patients Trial NA · Jinxi County People's Hospital · Southern Medical University, China · NCT06699433 A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multi Phase 1 · Fujian Cancer Hospital · Shanghai Henlius Biotech · NCT07160335 The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrh Phase N/A · Fujian Medical University Union Hospital · Union Hospital, Tongji Medical College, Huazhong University · NCT07172035 A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit Phase 1/Phase 2 · Local Institution - 0116 · Bristol-Myers Squibb · NCT07291076 Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Brea Phase 2/Phase 3 · Fujian Cancer Hospital · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05744687 Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients ( Phase 3 · Fujian Medical University Union Hospital · Fudan University · NCT05909332 Tumor Regression Grade As Predictor of Adjuvant Therapy Phase N/A · Fujian Medical University Union Hospital · Fujian Medical University Union Hospital · NCT06710665 A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors Phase 1 · Fujian Cancer Hospital · Heronova Pharmaceuticals · NCT07071090 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI Phase 2/Phase 3 · Department of Nuclear Medicine, First Affiliated Hospital of · First Affiliated Hospital of Fujian Medical University · NCT07209878 Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective NA · Fujian Cancer Hospital · Second Affiliated Hospital, Zhejiang University, School of M · NCT07402525 RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC Phase N/A · Fujian Medical University Union Hospital · Shanghai Chest Hospital · NCT07541521 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement Phase 1/Phase 2 · Local Institution - 6719 · Turning Point Therapeutics, Inc. · NCT03093116 IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer Phase 1/Phase 2 · Fujian Cancer Hospital · InxMed (Shanghai) Co., Ltd. · NCT05551507 A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. Phase 1/Phase 2 · Fujian Cancer Hospital · Advenchen Laboratories, LLC · NCT07392736
Look up another city
Look up another condition